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Abstract: Chronic conditions, whether genetic or acquired, impose a significant burden on health
care systems with high utilisation of hospital and emergency department resources. Self-
management is increasingly recognised as one of the pillars in models of care for those with long-
term medical conditions. Hereditary angioedema (HAE) is a rare genetic disorder inherited in an
autosomal dominant fashion. It is characterised by the occurrence of unpredictable attacks of
swelling (angioedema) affecting many body parts including subcutaneous tissues, the gut mucosa
and the upper airway. For those affected, it is associated with a high burden of illness and poor
quality of life as a result of its unpredictability and the threat of asphyxiation from upper airway
oedema or severe pain from abdominal involvement. Prompt recognition and appropriate treatment
are necessary to avoid the pain and suffering associated with attacks and to manage life-threatening
laryngeal swellings that around 50% of HAE patients will experience in their lifetime. Since the
early 2000s, a number of very effective, albeit expensive, treatment options have become available,
at least in some countries. Utilisation of these optionswithin awritten patient self-management plan
provides the most satisfactory treatment outcomes and improves patient quality of life. Successful
self-management depends on a productive partnership between patient and health care professional,
with patient education the cornerstone of a successful outcome. This is a dynamic process,
particularly in a condition such as HAE where frequency and severity of attacks may vary given
different life circumstances.
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Introduction
Self-management is increasingly recognised as a pillar in the models of care for
chronic or long term conditions.1
Chronic conditions, whether genetic or acquired, impose a significant burden on
health care systems with high utilisation of hospital and emergency department
resources. Co-ordinating optimal health care by incorporating self-management plans
is important to minimise the impact of these conditions at individual, community and
health system levels.2
This paper will address the application of self-management principles and the use of
a self-management treatment plan in Hereditary angioedema (HAE), a rare genetic
disorder.
HAE Background
HAE is characterised by the occurrence of unpredictable attacks of swelling
affecting many body parts. For those affected, it is associated with a high burden
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of illness and poor quality of life as a result of its unpre-
dictability and the threat of asphyxiation from upper air-
way oedema or severe pain from abdominal involvement.3
HAE is inherited as an autosomal dominant disorder
characterised by low or dysfunctional levels of C 1 INH.
The abnormality is in the SERPING1 gene mapped to
chromosome 11q12-q13.1. Over 700 mutations have been
described.4 While the majority of those affected inherit the
disorder, about 25% have a spontaneous mutation so they
lack the characteristic family history.5
There are three types described: HAE type 1 (HAE-1)
is the most common and results from abnormalities in one
of the gene alleles producing low levels of C 1 INH; HAE
type 2 (HAE-2) may have normal or elevated C1 INH
levels but the protein is dysfunctional. A third type has
been described that has normal levels of functional C 1
INH (HAE- nC1INH).6 In some with this variant, other
genetic mutations have been described, including muta-
tions of factor XII, plasminogen, angiopoietin 1 and kini-
nogen 1 genes.7–10
C1 INH is a key regulatory molecule in the comple-
ment, contact and coagulation pathways. Low or defective
levels of C1 INH result in unchecked complement activa-
tion as well as abnormalities in other pathways. Among its
actions, C1 INH inhibits kallikrein. Bradykinin, a key
mediator in the kallikrein system is responsible for capil-
lary leakage causing the swelling experienced by those
with HAE. Increased blood bradykinin levels have been
associated with clinical flares.11,12
The diagnosis of the classical HAE types depends on
the appropriate clinical history and the finding of low C4
levels, low or functionally abnormal C 1 INH levels and
normal C1q.13 Genotyping may be required, particularly
for accurate diagnosis of HAE-nC1INH patients.14
HAE has been described in all racial groups occurring in
1:50,000–1:150,000 of the population.15 Males and females
are equally affected but the condition tends to be more severe
in females. While the defect is present at birth, neonatal swel-
ling is rare. About 50% of cases present under 10 years with
the majority of affected individuals experiencing swellings by
late childhood and early teen years.16 Episodes of abdominal
pain in children may be easily overlooked or blamed on other
more common conditions. Swellings may occur throughout
life but tend to lessen in later life.16
Clinically, individuals with HAE experience angioedema
attacks (non-pruritic, non-pitting swelling) involving subcu-
taneous tissues, intestinal wall and the upper airway. About
50% of HAE patients experience at least one laryngeal attack
in their lives and before effective therapy, about 30% of HAE
patients died from asphyxiation.17
A number of triggers for attacks are identified by
individuals, the most common being trauma and stress,
but the majority of attacks are truly random and
unpredictable.11 Some individuals experience a transient,
non- pruritic lacy rash called erythema marginatum as
a prelude to a swelling although others may develop this
appearance without subsequent swelling.18,19
The true burden of having HAE comes from several
aspects. Laryngeal attacks are potentially life-threatening
and must be treated early and effectively, however if
definitive treatment is not available, tracheotomy may be
required as a life-saving procedure. Abdominal attacks
cause much misery as they are painful and may resemble
a bowel obstruction. The abdominal pain is caused by
oedema of the mucosa of any part of the gastrointestinal
tract. Many patients have undergone unnecessary laparo-
tomies in the past when the diagnosis has been missed.
Cutaneous swellings, particularly if they involve the
hands, feet, face and genitals, can interfere substantially
with daily life and may also be painful.
Frequency of attacks varies greatly between individuals
and within an individual’s lifetime. There may be periods of
very frequent attacks, particularly at times of psychological
and physical stress; at other times, the swellings may occur
uncommonly. Angioedema due to HAE differs from allergic
angioedema in that it usually has a slow onset and offset and
may last several days. It does not respond to usual treatments
such as antihistamines, oral corticosteroids or adrenaline
used to manage angioedema caused by an allergy.20
The unpredictable nature of attacks impacts indivi-
duals’ quality of life substantially as it is difficult to plan
ahead or make commitments for fear of an attack. Many of
those with HAE relate significant interruption to schooling
and career advancement because of their condition.21
HAE Management Strategies
A cornerstone of management in HAE is understanding the
need for early treatment of acute attacks with readily avail-
able specific therapies. Early therapy results in shorter time to
resolution of symptoms and shorter total attack duration
regardless of attack severity22. Replacing C1 INH or inhibit-
ing activated plasma kallikrein or bradykinin have become
the mainstay of acute therapy for HAE since the early 2000s,
at least in countries where these options are available. The
desirability for prompt recognition and treatment of an acute
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attack are major reasons why self-management has been
promoted for HAE patients.
When attack rates are frequent enough to impinge on
daily life and impair quality of life, consideration should be
given to long- term treatment, or prophylaxis (LTP).20
A third treatment strategy is the use of short- term prophy-
laxis (STP), where prophylactic medication is given in the
short- term to protect the individual from an increased risk of
an attack when undergoing procedures known to precipitate
attacks. These include invasive dental work and intubation
for surgery when there is a substantially increased risk of
inducing a life -threatening laryngeal attack.20
Until the early 2000’s few treatment options were
available to manage this condition. For acute attacks repla-
cement treatment with a blood product, C1 INH concen-
trate, has been available in some countries since the 1980’s
although in most its use was very restricted to severe
attacks only. It is administered intravenously so patients
presented to hospital emergency departments for infusions.
This usually entailed a number of delays and patients often
encountered barriers to obtaining this specific therapy.
Otherwise, only supportive therapy was available with
analgesia, fluid replacement and anti -emetics.
Acute attack management was dramatically changed
with the advent of the specific bradykinin receptor 2
antagonist, icatibant. This is administered by subcutaneous
injection and was shown to be highly efficacious in three
pivotal clinical trials.23
Its introduction into clinical practice resulted in major
positive impacts on quality of life of HAE patients as self-
administration is easily taught, the treatment is portable
and very effective, and its availability placed management
decisions firmly into the hands of patients no longer hav-
ing to tolerate delays and lack of understanding in emer-
gency departments.24–26
Ecallantide is a small, 60-amino acid, recombinant
protein inhibitor of plasma kallikrein, which was first
approved by the FDA in December 2009 for treatment of
acute attacks of HAE in patients and is now approved for
patients 12 years and over as a subcutaneous injection. It
inhibits kallikrein by blocking the plasma-binding site,
thereby stopping production of bradykinin and, conse-
quently, its effects.27 While it is available in the USA
use in other parts of the world is limited. There have
been cases of anaphylaxis reported with its use.
Craig et al28 conducted a study that specifically exam-
ined anaphylaxis associated with ecallantide. The study
included 230 individuals treated with ecallantide and
eight (3.5%) had anaphylactic reactions within an hour of
receiving ecallantide, none with the first dose.
For those with frequent attacks, two drugs, tranexamic
acid and danazol, have been available for many years in
most countries for LTP. Neither are completely effective
and danazol in particular, causes significant side effects in
many patients, particularly after long-term use.29,30
Since 2008, treatment options have expanded and
improved. C1 INH concentrate is available as plasma-
derived products (Berinert (CSL Behring) and Cinryze
(Shire,Takeda)) and as a recombinant C1 INH –
Ruconest (Pharming Group/Salix Pharmaceuticals).This
is a human recombinant C1 esterase inhibitor purified
from the milk of transgenic (genetically modified) rabbits.
The drug is intended to restore the level of functional C1
esterase inhibitor in the plasma, thereby treating an acute
attack of swelling.31 These products, administered intrave-
nously, are used for both acute treatment and for those
requiring LTP when C1 INH concentrate is administered at
frequent regular intervals in an attempt to prevent swel-
lings. Many patients have been taught self-cannulation so
these treatments can be on hand in the home for prompt
administration in the event of an acute attack or for con-
venient prophylactic therapy.
More recently a subcutaneously administered form of
Berinert has become available for LTP. Clinical studies
suggest that this product has greater efficacy and it is
certainly more convenient for patients to administer.32
The most recent addition to HAE therapeutic options is
lanadelumab, a monoclonal antibody directed against kal-
likrein. It is administered subcutaneously once a fortnight
making it the most convenient option for LTP to date. In
clinical trials it has been highly efficacious and has a good
side effect profile. It is now registered in several countries
and is in clinical use in the USA and in some European
countries.33
All the currently approved therapies are delivered by
injection or infusion. An orally delivered, small molecule
inhibitor of plasma kallikrein is in development and will
offer the opportunity to improve treatment for the disease
by making it more convenient for patients to take therapies.34
HAE Self-Management
Many features of HAE make it a condition very suitable
for patient self-management. Being a rare condition, most
medical practitioners will not have seen a patient with the
condition and many know very little about it. In this
situation, the patient becomes the expert and is able to
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guide medical staff regarding appropriate treatment for
symptoms. A knowledgeable patient is advantageous for
managing all chronic medical conditions but this is parti-
cularly pertinent for a rare disease when medical profes-
sionals are unlikely to have encountered the condition in
their experience.
As a strategy for managing chronic conditions, self-
management moves beyond education to teaching individuals
to be actively involved in treatment decisions, problem-
solving and appropriate medication administration.35 Most
importantly, self-management plans allow patients to maintain
independence and to have a degree of control over a chronic
condition, thus assisting in improving quality of life. The self-
management process involves problem-solving, decision
making, utilisation of medication and other treatments, part-
nering with health care professionals and undertaking regular
reviews and knowledge enhancement.36
There are various types of self-management plans and
these may be led by a medical person or the patient.
Whichever way they are devised, the goal is to empower
the individual with knowledge and skills to utilise medica-
tions or strategies in the most advantageous manner to
minimise impacts of the condition or symptoms on life-
style. Self-management plans can be devised for different
settings to be used by various individuals involved in care
delivery. Instructions may be for self-management or for
a family member or care- giver to administer treatment, or
for use by emergency department staff when attending
a patient with a rare or life-threatening emergency.
Depending on the particular medical condition, content
and design of a plan will differ.
Several steps are necessary in devising a self-
management plan independent of the chronic condition
experienced by the patient. Foremost is the individual’s
own values and preferences. Detailed discussions about
the particular medical condition, the various treatment
options available and their effects and side effects need
to be discussed so informed decisions can be made. The
medical practitioner needs to assess the knowledge, skills
and attitudes of the patient to determine the best way
forward. Careful discussion of how the plan is to be used
with checks on patient understanding performed. Follow
up visits for monitoring successful implementation, iden-
tification of any barriers or problems and continuing edu-
cation, are necessary. Appropriate notification of the care
plan in the medical file is the final step in the process.2
Self-management plans have been part of routine prac-
tice for patients with chronic diseases such as asthma and
diabetes for many years. More recently there have been very
effective management plans devised for those at risk of
anaphylaxis so these individuals are coached in early recog-
nition of potentially life-threatening signs and symptoms and
early institution of emergency treatment with appropriate
drugs.37 In many disease states, self-management programs
are proven models for successful chronic disease manage-
ment leading to fewer hospital presentations and improved
quality of life and are now adopted as standard practice in
many countries including the USA, Australia, United
Kingdom, Canada and New Zealand.38
The Cochrane Collaboration has conducted evidence-
based reviews of a number of self-management programs
such as those for asthma with positive findings supporting
their role in clinical practice.39
As outlined above, treatment options for those with
HAE have increased considerably over the last decade, at
least in some countries. There are various treatment
options available for acute management and LTP so
patients do have some choice in how to manage their
condition. Knowing how to manage HAE when there is
a need for invasive dental work or surgery is also very
important. The goals of devising individual management
plans is to decrease morbidity, prevent mortality and
improve quality of life by giving a degree of control
over an unpredictable condition. There are various steps
in the process of constructing such a plan, beginning with
patient education consisting of a careful discussion about
available treatment options, their effects and side effects.
Ideally, one or more family members or a carer should be
involved in this process as well. Writing the action plan,
discussing its implementation and checking that the patient
understands it is vital. Monitoring its use, gauging the
appropriateness of actions taken, and adjusting the plan
according to the patient’s attack rate are the final steps for
ensuring maximal benefit. Self-management plan construc-
tion and implementation should be seen as a dynamic
process that adapts to individual needs at various times.
Specific Components of HAE
Management Plans
The first step in the HAE self-management process is to
provide education and written information that can be
presented to emergency department staff if a patient
needs to present to hospital. This information may be in
the form of a letter,emergency card, website contact or
documents on a device. This is a rare condition and the
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vast majority of emergency department staff will not have
had the opportunity to treat an HAE attack.
Secondly, the plan must incorporate details about treat-
ing an acute attack. International guidelines state that all
patients should have at least two doses of acute treatment
on hand at all times.20 Other information to record
includes when to treat (early in the attack; ideally within
the first few hours); when to repeat treatment; what to do
when on demand treatment is not available and how to
handle the medication including appropriate storage
instructions. Specific instructions of what is needed for
travel, school or the workplace is also necessary.
Some but not all HAE patients may require LTP. How
this need is determined varies and depends on many fac-
tors including local regulations. In most countries, danazol
is available but discussions concerning effects and side
effects need to be undertaken before a patient can make
an informed choice. In many countries C 1 INH concen-
trate for IV administration is the other option, and like-
wise, careful discussion concerning its administration,
storage and other logistics need to be had with the patient.
Very recently two more convenient and highly efficacious
forms of LTP have become available at least in some
countries. Both Berinert SC (Haegarda) and lanadelumab
(Takzhyro) are administered subcutaneously making them
far more attractive options. In ideal circumstances, factors
other than numerical attack rates must be considered in
gauging the need for LTP, including impact on a particular
patient’s life, distance from emergency medical treatment
centres, and presence of particular stressors. Patient pre-
ferences, success with on demand treatments and ease of
venous access are also considerations.40
Adaptation of HAE management plans will be neces-
sary for special situations such as pregnancy and lactation,
and for paediatric patients.
Conclusions
Chronic diseases including genetic disorders impose signifi-
cant burden on both patients and the health care systems.
Engaging such patients in self-management to optimally
utilise therapies is an important step in cost containment
and improved health care outcomes. HAE, a rare genetic
disorder for which several new, very expensive, treatment
modalities are now available, provides a good example of
a life-long, chronic condition where an educated patient,
trained in appropriate self-management, can experience bet-
ter outcomes and quality of life. Patients with rare conditions
become the experts in management of their condition and
with the appropriate tools can optimise their own manage-
ment while providing useful information for non-expert
health professionals.
The basic principles of HAE self-management are patient
and carer education tailored to individual knowledge, skills
and attitudes, written treatment plans and regular review and
revision depending on changing circumstances. Future needs
in HAE management include patient-centred research to
assess effectiveness and adherence to written treatment
plans and to further refine design to accommodate evolving
treatment options and patient needs.
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